𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Placebo and nocebo effects in randomized double-blind clinical trials of agents for the therapy for fatigue in patients with advanced cancer

✍ Scribed by Maxine de la Cruz; David Hui; Henrique A. Parsons; Eduardo Bruera

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
177 KB
Volume
116
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

BACKGROUND:

A significant response to placebo in randomized controlled trials of treatments for cancer‐related fatigue (CRF) had been reported. A retrospective study was conducted to determine the frequency and predictors of response to placebo effect and nocebo effects in patients with CRF treated in those trials.

METHODS:

The records of 105 patients who received placebo in 2 previous randomized clinical trials conducted by this group were reviewed. The proportion of patients who demonstrated clinical response to fatigue, defined as an increase in Functional Assessment of Chronic Illness Therapy‐Fatigue score of ≥7 from baseline to Day 8, and the proportion of patients with a nocebo effect, defined as those reporting >2 side effects, were determined. Baseline patient characteristics and symptoms recorded using the Edmonton Symptom Assessment Scale (ESAS) were analyzed to determine their association with placebo and nocebo effects.

RESULTS:

Fifty‐nine (56%) patients had a placebo response. Worse baseline anxiety and well‐being subscale score (univariate) and well‐being (multivariate) were significantly associated with placebo response. Commonly reported side effects were insomnia (79%), anorexia (53%), nausea (38%), and restlessness (34%). Multivariate analysis indicated that worse baseline (ESAS) sleep, appetite, and nausea were associated with increased reporting of the corresponding side effects.

CONCLUSIONS:

Greater than half of advanced cancer patients enrolled in CRF trials had a placebo response. Worse baseline physical well‐being score was associated with placebo response. Patients experiencing specific symptoms at baseline were more likely to report these as side effects of the medication. These findings should be considered in the design of future CRF trials. Cancer 2010. © 2009 American Cancer Society.

📜 SIMILAR VOLUMES

A randomized, double-blind, placebo-cont
A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients
✍ Fabrizio Stocchi; Rupam Borgohain; Marco Onofrj; Anthony H.V. Schapira; Mohit Bh 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 446 KB 👁 2 views

## Abstract Safinamide is an α‐aminoamide with both dopaminergic and nondopaminergic mechanisms of action evaluated as an add‐on to dopamine agonist (DA) therapy in early‐stage PD. In this 24‐week, double‐blind study, patients with early PD receiving a stable dose of a single DA were randomized to

The effect of moderate-dose corticostero
The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: Findings of a prospective, randomized, double-blind, placebo-controlled trial
✍ Chung-E Tseng; Jill P. Buyon; Mimi Kim; H. Michael Belmont; Meggan Mackay; Betty 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB 👁 2 views

## Abstract ## Objective Serial measurements of anti–double‐stranded DNA (anti‐dsDNA) and complement are routine in the management of systemic lupus erythematosus (SLE), but their utility as biomarkers in preemptive treatment to prevent flares remains a subject of controversy. We hypothesized that

Ciprofloxacin or metronidazole for the t
Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: A randomized, double-blind, placebo-controlled pilot study
✍ Kelvin T. Thia; Uma Mahadevan; Brian G. Feagan; Cindy Wong; Alan Cockeram; Alain 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 99 KB 👁 2 views

Background: Although metronidazole and ciprofloxacin are used to treat perianal Crohn's disease (CD), no placebo-controlled trials have been performed. ## Methods: We performed a placebo-controlled pilot trial to evaluate the efficacy and safety of metronidazole and ciprofloxacin in patients with

LJP 394 for the prevention of renal flar
LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: Results from a randomized, double-blind, placebo-controlled study
✍ Donato Alarcón-Segovia; James A. Tumlin; Richard A. Furie; James D. McKay; Mario 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 188 KB 👁 2 views

## Abstract ## Objective To determine whether LJP 394 delays or prevents renal flare in patients with systemic lupus erythematosus (SLE) and a history of renal disease. ## Methods In a 76‐week, double‐blind, placebo‐controlled study, 230 SLE patients were randomized to receive 16 weekly doses of